EuroIntervention PCRonline - Connecting with the community

Just accepted article

Safety and Efficacy of a Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent in Patients with Diabetes: the EVOLVE II Diabetes Substudy


As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers. To read the full content of this article, please download the PDF.

1. The Christ Hospital Heart & Vascular Center/The Lindner Center, UNITED STATES; 2. MonashHEART, Southern Health, Monash Medical Centre, Clayton, Australia; 3. Hospital Clinic, University of Barcelona, Spain; 4. Centre Hôpital Universitaire Rangueil, Toulouse, France; 5. Hospital La Paz, Madrid, Spain; 6. Pauls Stradins Clinical University Hospital, University of Latvia, Riga, Latvia; 7. McMaster University and Hamilton Health Sciences, Hamilton, Canada; 8. Centre Hospitalier de Lagny - Marne La Vallée, Jossigy, France; 9. Clinique Saint-Hilaire - Centre Frédéric Joliot, Rouen, France; 10. Morton Plant Mease Baycare Health System, Clearwater, FL; 11. Turku University Hospital, Turku, Finland; 12. UNC Rex Healthcare, Raleigh, NC; 13. Wellstar Kennestone Hospital, Marietta, GA USA; 14. Imeldaziekenhuis, Bonheiden Belgium; 15. Boston Scientific Corporation, Marlborough MA USA; 16. Boston Scientific Corporation, Marlborough MA USA; 17. Bern University Hospital, Bern, Switzerland


Aims: Bioabsorbable-polymer drug-eluting stents (DES) may reduce inflammation and delayed healing associated with some permanent polymer-coated DES. Whether late clinical outcomes are improved, particularly among patients with medically-treated diabetes, is unknown.

Methods and results: SYNERGY is a thin-s…

– OR –